Alzheimer’s disease, a progressive neurodegenerative disorder that affects millions worldwide, has a long preclinical stage. It potentially begins decades before clinical symptoms become apparent.
Continue Reading this article here
Blood biomarkers could detect earliest signs of Alzheimer’s disease—and slow its progression
